全文获取类型
收费全文 | 8816篇 |
免费 | 396篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 165篇 |
妇产科学 | 64篇 |
基础医学 | 1060篇 |
口腔科学 | 200篇 |
临床医学 | 560篇 |
内科学 | 2614篇 |
皮肤病学 | 123篇 |
神经病学 | 520篇 |
特种医学 | 321篇 |
外科学 | 1492篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 142篇 |
眼科学 | 121篇 |
药学 | 480篇 |
中国医学 | 12篇 |
肿瘤学 | 1282篇 |
出版年
2024年 | 9篇 |
2023年 | 79篇 |
2022年 | 191篇 |
2021年 | 299篇 |
2020年 | 149篇 |
2019年 | 197篇 |
2018年 | 224篇 |
2017年 | 188篇 |
2016年 | 239篇 |
2015年 | 226篇 |
2014年 | 290篇 |
2013年 | 359篇 |
2012年 | 647篇 |
2011年 | 702篇 |
2010年 | 423篇 |
2009年 | 333篇 |
2008年 | 564篇 |
2007年 | 587篇 |
2006年 | 583篇 |
2005年 | 547篇 |
2004年 | 523篇 |
2003年 | 505篇 |
2002年 | 496篇 |
2001年 | 71篇 |
2000年 | 74篇 |
1999年 | 78篇 |
1998年 | 101篇 |
1997年 | 74篇 |
1996年 | 41篇 |
1995年 | 58篇 |
1994年 | 48篇 |
1993年 | 45篇 |
1992年 | 35篇 |
1991年 | 49篇 |
1990年 | 25篇 |
1989年 | 26篇 |
1988年 | 24篇 |
1987年 | 9篇 |
1986年 | 20篇 |
1985年 | 16篇 |
1984年 | 18篇 |
1983年 | 10篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 14篇 |
1976年 | 5篇 |
1969年 | 4篇 |
排序方式: 共有9277条查询结果,搜索用时 11 毫秒
41.
Henrik Fox Takayuki Gyoten Sebastian V Rojas Volker Lauenroth Sabina Günther Ren Schramm Jan F Gummert Michiel Morshuis 《Interactive Cardiovascular and Thoracic Surgery》2022,35(1)
Open in a separate window OBJECTIVESPump thrombosis remains a major challenge in heart failure patients with left ventricular HeartWare assist device. Current International Society for Heart and Lung Transplantation recommendations favour surgical pump exchange over lysis because safety and efficacy of lysis has been controversially reported. This study summarizes our experience on our HeartWare thrombosis prevention strategy as well as thrombolysis through implementation of our institutional standardized HeartWare assist device protocol.METHODSOutcomes of all HeartWare thrombosis patients admitted between 2010 and 2020 were analysed. Thrombolysis therapy using tissue plasminogen activator was used as the first-line therapy in this study and thrombolysis therapy efficacy was defined as freedom from stroke, bleeding, recurrent HeartWare assist device thrombosis or surgical device exchange within 30 days after lysis application.RESULTSA total of 507 patients have been included in this study and 66 patients (13%) collectively developed a first HeartWare-thrombosis after a median of 12 months (8–22 months) after HeartWare implantation. Forty patients were treated with unstandardized lysis, of whom 7 patients had thrombolysis associated complications, such as incomplete thrombus resolution requiring surgical pump exchange in 4 patients, but also intracranial haemorrhage occurring in 3 patients. Three patients died in the non-protocol group. Eight device thrombosis patients were treated according to our protocol, showing no lysis-associated complication.CONCLUSIONSDespite current recommendations, preferring surgical HeartWare pump exchange in thrombosis, thrombolysis therapy for first HeartWare thrombosis can be safe and effective in a standardized protocol setting, including anticoagulation adjustment and intensified blood pressure control management. 相似文献
42.
Yosuke Nakai Yusuke Nishikawa Takayuki Saito Hisao Suda 《Interactive Cardiovascular and Thoracic Surgery》2022,35(2)
Takayasu arteritis results in a variety of vascular symptoms, and there are some cases in which progressive vascular lesions require surgical intervention. We present a case with ascending aortic aneurysm, right common carotid artery stenosis, left common carotid artery occlusion and left subclavian artery stenosis caused by Takayasu arteritis that was successfully treated with total arch replacement and ascending aorta to right internal carotid artery bypass. 相似文献
43.
Shin-ichiro Ohmura Yoichiro Homma Takayuki Masui Toshiaki Miyamoto 《Internal medicine (Tokyo, Japan)》2022,61(7):997
Objective To investigate the risk factors for the development of Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) undergoing methotrexate (MTX) therapy. Methods This single-center retrospective cohort study included consecutive patients with RA who received MTX for at least one year. The study population was divided into PCP and non-PCP groups, depending on the development of PCP, and their characteristics were compared. We excluded patients who received biologic disease-modifying anti-rheumatic drugs (DMARDs), Janus kinase inhibitors, and anti-PCP drugs for prophylaxis. Results Thirteen patients developed PCP, and 333 did not develop PCP. At the initiation of MTX therapy, the PCP group had lower serum albumin levels, a higher frequency of pulmonary disease and administration of DMARDs, and received a higher dosage of prednisolone (PSL) than the non-PCP group. A multivariate Cox regression analysis revealed that the concomitant use of PSL [hazard ratio (HR) 5.50, p=0.003], other DMARDs (HR 5.98, p=0.002), and serum albumin <3.5 mg/dL (HR 4.30, p=0.01) were risk factors for the development of PCP during MTX therapy. Patients with these risk factors had a significantly higher cumulative probability of developing PCP than patients who lacked these risk factors. Conclusion Clinicians should pay close attention to patients with RA who possess risk factors for the development of PCP during MTX therapy. 相似文献
44.
Kota Watanabe Takayuki Nakamura Akio Iwanami Naobumi Hosogane Takashi Tsuji Ken Ishii Masaya Nakamura Yoshiaki Toyama Kazuhiro Chiba Morio Matsumoto 《BMC musculoskeletal disorders》2012,13(1):1-6
The underlying purpose of this commentary and position paper is to achieve evidence-based recommendations on prevention of work-related musculoskeletal disorders (MSDs). Such prevention can take different forms (primary, secondary and tertiary), occur at different levels (i.e. in a clinical setting, at the workplace, at national level) and involve several types of activities. Members of the Scientific Committee (SC) on MSDs of the International Commission on Occupational Health (ICOH) and other interested scientists and members of the public recently discussed the scientific and clinical future of prevention of (work-related) MSDs during five round-table sessions at two ICOH conferences (in Cape Town, South Africa, in 2009, and in Angers, France, in 2010). Approximately 50 researchers participated in each of the sessions. More specifically, the sessions aimed to discuss new developments since 1996 in measures and classification systems used both in research and in practice, and agree on future needs in the field. The discussion focused on three questions: At what degree of severity does musculoskeletal ill health, and do health problems related to MSDs, in an individual worker or in a group of workers justify preventive action in occupational health? What reliable and valid instruments do we have in research to distinguish ??normal musculoskeletal symptoms?? from ??serious musculoskeletal symptoms?? in workers? What measures or classification system of musculoskeletal health will we need in the near future to address musculoskeletal health and related work ability? Four new, agreed-upon statements were extrapolated from the discussions: 1. Musculoskeletal discomfort that is at risk of worsening with work activities, and that affects work ability or quality of life, needs to be identified. 2. We need to know our options of actions before identifying workers at risk (providing evidence-based medicine and applying the principle of best practice). 3. Classification systems and measures must include aspects such as the severity, frequency, and intensity of pain, as well as measures of impairment of functioning, which can help in prevention, treatment and prognosis. 4. We need to be aware of economic and/or socio-cultural consequences of classification systems and measures. 相似文献
45.
Akira Yoneda Shunsuke Murakami Hanako Tetsuo Saeko Fukui Takayuki Miyoshi Tatsuya Okamoto Amane Kitasato Hiroaki Takeshita Tamotsu Kuroki 《Clinical Case Reports》2022,10(5)
We describe a case of pancreatic tumor associated with a giant type IV hiatal hernia that had prolapsed into the posterior mediastinum. Hiatal hernia repair should be performed first because it enables laparoscopic distal pancreatectomy to be performed in the normal anatomical position. 相似文献
46.
Ayuko Yamashita Mineaki Kitamura Yohei Tateishi Kenta Torigoe Kumiko Muta Yasushi Mochizuki Tsuyoshi Izumo Takayuki Matsuo Akira Tsujino Hideki Sakai Hiroshi Mukae Tomoya Nishino 《Internal medicine (Tokyo, Japan)》2022,61(8):1133
Objective The quality of life and activities of daily living (ADL) are generally poor among dialysis patients after intracerebral hemorrhaging, and their precise clinical course remains unclear. In addition, the association between the severity of cerebral hemorrhaging and the long-term prognosis in these patients has not been fully elucidated. This study aimed to evaluate the subsequent prognosis of hemodialysis patients who survived the acute phase of intracerebral hemorrhaging. Methods We included hemodialysis patients who were admitted to Nagasaki University Hospital between 2007 and 2015 for intracerebral hemorrhaging treatment. After excluding cases of in-hospital death, survivors were classified using the 5-point modified Rankin Scale (mRS), which specifically measures the ADL in patients with cerebrovascular diseases. The patients were followed up at the medical facilities to which they were transferred in the same medical zone until 2017. Results Out of 91 patients with cerebral hemorrhaging (65±11 years old, 66% men, hemodialysis duration 108±91 months), 62 survived until discharge. Twenty-one patients died during observation, largely due to infectious diseases, such as sepsis and pneumonia (n=16, 76%). Compared to patients with mRS 0-4 (n=31), those with mRS 5 (n=31) showed a significantly poorer prognosis. The hazard ratio adjusted for age and antiplatelets was 13.7 (95% confidence interval: 3.88-63.7, p<0.001). Conclusion Hemodialysis patients with intracerebral hemorrhaging who were bedridden showed poor outcomes. The major causes of death were infections. Therefore, these patients should be carefully monitored for infections in order to improve their prognosis. 相似文献
47.
Seizaburo Masuda Kazuki Ota Rei Okazaki Ryoko Ishii Keiho Cho Yuki Hiramatsu Yuko Adachi Sayo Koseki Eri Ueda Isao Minami Tetsuya Yamada Takayuki Watanabe 《Internal medicine (Tokyo, Japan)》2022,61(8):1125
Objective This study analyzed the clinical and laboratory parameters that might influence the clinical outcomes of patients with type 2 diabetes who develop diabetic ketoacidosis (DKA), which has not been well investigated. Methods We reviewed the clinical and laboratory data of 158 patients who were hospitalized due to DKA between January 2006 and June 2019 and compared the data of patients stratified by the type of diabetes. In addition, the patients with type 2 diabetes were subdivided according to age, and their clinical and laboratory findings were evaluated. Results Patients with type 2 diabetes had a longer symptom duration associated with DKA, higher body mass index (BMI), and higher C-peptide levels than those with type 1 diabetes (p<0.05). Among patients with type 2 diabetes, elderly patients (≥65 years old) had a longer duration of diabetes, higher frequency of DKA onset under diabetes treatment, higher effective osmolarity, lower BMI, and lower urinary C-peptide levels than nonelderly patients (<65 years old) (p<0.05). A correlation analysis showed that age was significantly negatively correlated with the index of insulin secretory capacity. Conclusion Patients with DKA and type 2 diabetes had a higher BMI and insulin secretion capacity than those with type 1 diabetes. However, elderly patients with type 2 diabetes, unlike younger patients, were characterized by a lean body, impaired insulin secretion, and more frequent DKA development while undergoing treatment for diabetes. 相似文献
48.
Prevention of Acute Lung Allograft Rejection in Rat by CTLA4Ig 总被引:6,自引:0,他引:6
Takeshi Shiraishi Yohichi Yasunami Megumi Takehara Toshimitsu Uede Katsunobu Kawahara Takayuki Shirakusa 《American journal of transplantation》2002,2(3):223-228
CTLA4 immunoglobulin (CTLA4Ig), which binds with a high affinity to B7-1 and B7-2, interrupts T-cell activation by inhibiting costimulatory signal. CTLA4Ig has been used in hopes of achieving antigen-specific tolerance induction in several solid organ transplants. In lung allograft rejection, however, its use has been controversial in terms of its effect on prevention of rejection. In the present study, the effect of murine CTLA4Ig on rat-lung allograft rejection was investigated. Rat left-lung transplantation was performed in an RT1 incompatible donor (Brown Norway; BN)-recipient (F344) combination. All allografts (n = 12) without any treatment were rejected within 7 days after transplantation. A single injection of murine form CTLA41g at a dose of 100 microg intraperitoneally (ip) or intravenously (iv) on day 1 post-transplantation achieved long-term graft survival (>90days) in 2/5 (40%) and 3/8 (38%), respectively. Moreover, 6/7 (86%) allografts in rats that received iv injection of 500 microg CTLA4Ig survived more than 90days. Allograft survival in the CTLA4Ig 500 microg iv recipient group was significantly longer than that in the no-treatment control or control immunoglobulin group (p <0.01). Four out of seven recipients bearing functional allografts for more than 90 days with the CTLA4Ig treatment accepted donor-specific skin grafts, whereas all third-party skin grafts (n=3) were rejected. Prevention of rat-lung allograft rejection could be achieved by intravenous administration of CTLA4Ig, resulting in long-term allograft survival with acceptance of donor-specific skin grafts. 相似文献
49.
Koji Goto Satoshi Hagiwara Seigo Hidaka Shunsuke Yamamoto Junya Kusaka Norihisa Yasuda Chihiro Shingu Takayuki Noguchi 《Journal of anesthesia》2010,24(1):11-16
Purpose
To examine the effect of landiolol on cerebral blood flow in patients with normal or deteriorated cardiac function. 相似文献50.
Yasuhiro Katsumata Masayoshi Harigai Yasushi Kawaguchi Chikako Fukasawa Makoto Soejima Tokiko Kanno Katsuji Nishimura Takayuki Yamada Hisashi Yamanaka Masako Hara 《BMC musculoskeletal disorders》2010,11(1):13